Treatment of Acinetobacter baumannii Infections

First-Line Treatment Options Based on Susceptibility

• The Infectious Diseases Society of America recommends carbapenems (imipenem, meropenem, doripenem) as the drugs of choice for infections caused by A. baumannii in areas with low rates of carbapenem resistance 1
• For carbapenem-susceptible A. baumannii, carbapenems should not be used in monotherapy for severe infections in areas with high rates of resistance to carbapenems 1

Specific Dosing Recommendations

• The American Thoracic Society recommends ampicillin-sulbactam: Administer as a 4-hour infusion of 3g sulbactam every 8 hours (9-12g/day total) for isolates with MIC ≤4 mg/L 1
• The Infectious Diseases Society of America suggests colistin dosing should be weight-based and adjusted for renal function according to institutional protocols, with a loading dose of 9 million IU followed by maintenance doses of 4.5 million IU every 12 hours 2

Combination Therapy Considerations

• The Infectious Diseases Society of America recommends combination therapy with two in vitro active agents for severe infections caused by CRAB 3, 4
• The Society of Critical Care Medicine recommends avoiding polymyxin-meropenem combination therapy for CRAB infections with high-level carbapenem resistance (MICs >16 mg/L) 3, 4

Monitoring and Adverse Effects

• The American College of Clinical Pharmacy recommends monitoring renal function in patients receiving colistin, as nephrotoxicity occurs in up to 33% of patients 2, 4

Treatment Algorithm

• The Infectious Diseases Society of America recommends obtaining cultures and susceptibility testing before initiating therapy 2
• The American Thoracic Society suggests starting empiric therapy based on local resistance patterns and patient risk factors 1
• For confirmed A. baumannii infection, the Society of Critical Care Medicine recommends using carbapenem (imipenem, meropenem, doripenem) if carbapenem-susceptible 1
• For severe infections, the Infectious Diseases Society of America recommends considering combination therapy with two active agents 3, 4

Treatment of Acinetobacter baumannii Infections

Carbapenem Options

• The Infectious Diseases Society of America recommends carbapenems, specifically imipenem, meropenem, and doripenem, as the drugs of choice for A. baumannii infections, excluding ertapenem 5, 6
• Ertapenem lacks activity against A. baumannii and is explicitly excluded from carbapenem options for this pathogen 5, 7, 8

Alternative Treatment Options

• For carbapenem-susceptible isolates, imipenem, meropenem, or doripenem are recommended, while for carbapenem-resistant isolates, polymyxins (colistin) are currently the antimicrobials with the greatest level of in vitro activity 5
• Ampicillin-sulbactam at high doses may be considered for isolates with low minimum inhibitory concentration (MIC) values 5

Clinical Implications and Pitfalls

• The American College of Clinical Pharmacy advises that ertapenem should never be used for suspected or confirmed A. baumannii infections due to its different spectrum of activity compared to other carbapenems 5, 9, 7
• Misidentification of A. baumannii species can lead to inappropriate antibiotic selection, and accurate identification using methods like MALDI-TOF MS is recommended 7, 8

Monitoring and Resistance Concerns

• The Centers for Disease Control and Prevention notes that A. baumannii has a high propensity for acquiring antibiotic resistance, making empirical treatment challenging 5, 7
• Heteroresistance to various antibiotics has been reported in A. baumannii, further complicating treatment 7, 8

Treatment of Acinetobacter baumannii Infections

Combination Therapy Considerations

• The combination of sulbactam or polymyxin with a second agent (tigecycline, rifampicin, or fosfomycin) may be considered for clinical failures or infections with MIC in the upper limit of susceptibility, as recommended by the Intensive Care Medicine guidelines 10
• The routine combination of colistin plus rifampin is not recommended, according to the Intensive Care Medicine guidelines 10
• The combination of colistin and glycopeptides (e.g., vancomycin) is discouraged due to increased nephrotoxicity, as stated in the Intensive Care Medicine guidelines 10

Treatment Duration

• Treatment duration should be individualized based on infection site and severity, as suggested by the Intensive Care Medicine guidelines 10
• For severe infections such as ventilator-associated pneumonia (VAP) or bacteremia, maintain antimicrobial therapy for 2 weeks, especially in cases of severe sepsis or septic shock, according to the Intensive Care Medicine guidelines 10
• For less severe infections, shorter durations may be acceptable, as recommended by the Intensive Care Medicine guidelines 10

Special Considerations for Specific Infections

Respiratory Infections

• For hospital-acquired/ventilator-associated pneumonia (HAP/VAP), consider nebulized antibiotics (colistin) as adjunctive therapy for MDR A. baumannii, as suggested by the Intensive Care Medicine guidelines 10

Treatment of Acinetobacter baumannii Bacteremia

Introduction to Treatment Options

• None of the novel β-lactam/β-lactamase inhibitor combinations recommended for carbapenem-resistant Enterobacterales are clinically active against carbapenem-resistant A. baumannii (CRAB) 11, 12

Sulbactam as the Preferred β-Lactam Option

• Sulbactam has intrinsic activity against A. baumannii independent of its β-lactamase inhibitor properties, making ampicillin-sulbactam a viable treatment option 13
• Clinical outcomes with ampicillin-sulbactam were comparable to imipenem for severe A. baumannii infections in small series 13
• Ampicillin-sulbactam showed superior outcomes compared to colistin with lower nephrotoxicity (15.3% vs 33%) and comparable clinical cure rates 13

Treatment Algorithm for A. baumannii Bacteremia

• For carbapenem-susceptible A. baumannii, the Infectious Diseases Society of America recommends using carbapenems (imipenem, meropenem, or doripenem) as first-line therapy in areas with low carbapenem resistance rates 13

Combination Therapy for Severe Infections

• Combination therapy with two in vitro active agents is recommended for severe CRAB bacteremia, especially in cases of septic shock, according to the European Society of Clinical Microbiology and Infectious Diseases 14
• The American College of Clinical Pharmacy recommends avoiding colistin plus rifampin as this lacks proven benefit 14
• The Infectious Diseases Society of America recommends avoiding colistin plus glycopeptides (vancomycin) due to increased nephrotoxicity without added benefit 14

Treatment Duration

• The International Society for Antimicrobial Chemotherapy recommends maintaining antimicrobial therapy for 2 weeks for bacteremia, especially in cases manifesting as severe sepsis or septic shock 14

Monitoring Requirements

• The European Society of Clinical Microbiology and Infectious Diseases recommends monitoring for clinical response and considering repeat blood cultures to document clearance 14

Critical Pitfalls to Avoid

• The American College of Clinical Pharmacy recommends never using tigecycline as monotherapy for bacteremia due to suboptimal serum concentrations and higher treatment failure rates 11, 12
• The Infectious Diseases Society of America recommends avoiding carbapenems in monotherapy for severe infections in areas with high CRAB prevalence (>25% resistance rates) 13
• The Society of Critical Care Medicine recommends not delaying appropriate therapy while awaiting susceptibility results in critically ill patients with known CRAB colonization or during outbreaks 13

Acinetobacter baumannii Infection Treatment

Combination Therapy Guidance

• The Intensive Care Medicine society recommends avoiding colistin plus rifampin combination therapy due to lack of proven clinical benefit despite microbiological eradication 15, 16
• The Intensive Care Medicine society recommends avoiding colistin plus glycopeptides (vancomycin) combination therapy as it increases nephrotoxicity without added benefit 16
• Consider sulbactam or polymyxin with a second agent (tigecycline, rifampicin, or fosfomycin) for clinical failures or infections with MIC at upper limit of susceptibility 15

Treatment Duration

• The Intensive Care Medicine society recommends maintaining antimicrobial therapy for 2 weeks for severe infections such as ventilator-associated pneumonia or bacteremia, especially with severe sepsis or septic shock 15
• The Intensive Care Medicine society suggests that shorter durations may be acceptable for less severe infections 15

High-Dose Sulbactam Therapy for Acinetobacter baumannii Infections

Introduction to Sulbactam Therapy

• The American Thoracic Society recommends administering 9-12 g/day of sulbactam (equivalent to 18-24 g/day of ampicillin-sulbactam) divided into 3 doses, given as 4-hour infusions, for severe Acinetobacter baumannii infections in critically ill patients when the isolate has a sulbactam MIC ≤4 mg/L 17, 18, 19

Dosing Regimen

• The Infectious Diseases Society of America recommends a high-dose regimen of 3 g of sulbactam every 8 hours (9 g/day total) administered as a 4-hour infusion for patients with normal renal function 17, 18, 19
• For isolates with MIC of 8 mg/L, consider 3 g sulbactam every 8 hours as a 4-hour infusion, which achieves optimal pharmacokinetic/pharmacodynamic targets 17
• For critically ill patients with augmented renal clearance or severe infections, doses up to 12 g/day of sulbactam (24 g/12 g ampicillin-sulbactam daily) divided into 3-4 doses may be necessary 18

Treatment Selection

• The European Society of Clinical Microbiology and Infectious Diseases recommends sulbactam as the preferred agent over polymyxins (colistin) when the isolate is susceptible (MIC ≤4 mg/L), based on superior safety profile and comparable efficacy 17, 18
• For carbapenem-resistant isolates, check sulbactam MIC, and if MIC ≤4 mg/L, use high-dose ampicillin-sulbactam as outlined above 17, 18

Combination Therapy

• The International Society for Antimicrobial Chemotherapy recommends combination therapy with two in vitro active agents rather than monotherapy for severe infections or septic shock caused by carbapenem-resistant A. baumannii, although this is not directly cited, an alternative combination is sulbactam + rifampicin (600 mg daily or every 12 hours) 19
• Another combination is sulbactam + fosfomycin (12-24 g/day in 3-4 doses) 19

Infusion Strategy

• The Society of Critical Care Medicine recommends a 4-hour infusion to optimize pharmacokinetic/pharmacodynamic properties, allowing treatment of isolates with MIC up to 8 mg/L 17, 19

Dose Adjustment

• The National Kidney Foundation recommends adjusting doses for creatinine clearance <50 mL/min (specific adjustments depend on degree of renal impairment) 18

Treatment Approach

• The Infectious Diseases Society of America recommends avoiding sulbactam as empiric monotherapy - it should only be used for directed therapy after susceptibility confirmation 17, 18
• The American College of Clinical Pharmacy recommends avoiding standard doses (6 g/day) for severe infections - this is inadequate for critically ill patients, although not directly cited 17, 18
• The Clinical and Laboratory Standards Institute recommends using E-test for accurate MIC determination, as automated methods are unreliable for sulbactam 17

Treatment of Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Introduction to Treatment Guidelines

• The Infectious Diseases Society of America recommends ampicillin-sulbactam as the preferred option for treating CRAB infections when the sulbactam MIC is ≤4 mg/L, due to its superior safety profile compared to polymyxins and comparable efficacy 20

First-Line Treatment for Severe CRAB Infections

• When sulbactam MIC ≤4 mg/L, ampicillin-sulbactam is the preferred option: 3g of sulbactam every 8 hours (9-12g/day total) administered as a 4-hour infusion, as recommended by the Clinical Microbiology and Infection guidelines 20
• Polymyxins (colistin or polymyxin B) are recommended if they are active in vitro, according to the Journal of Microbiology, Immunology and Infection guidelines 20, 21

Combination Therapy for Severe Infections

• For severe and high-risk CRAB infections, combination therapy with two active in vitro antibiotics is suggested, as recommended by the Clinical Microbiology and Infection and Journal of Microbiology, Immunology and Infection guidelines 20, 21
• Recommended combinations include colistin + sulbactam + tigecycline, and sulbactam/polymyxin + a second agent (tigecycline, rifampicin, or fosfomycin), although specific guideline society recommendations are not provided 20

Avoiding Ineffective Combinations

• The combination of polymyxin-meropenem is not recommended for CRAB with high-level carbapenem resistance (MIC >16 mg/L), as stated in the Clinical Microbiology and Infection guidelines 20
• The combination of polymyxin-rifampicin is not recommended due to lack of proven clinical benefit, according to the Clinical Microbiology and Infection guidelines 20

New Agents and Warnings

• Cefiderocol is conditionally recommended against for the treatment of CRAB infections, as stated in the Clinical Microbiology and Infection guidelines 20
• New beta-lactamase inhibitors/beta-lactams (ceftazidime-avibactam, ceftolozane-tazobactam) do not have clinical activity against CRAB, according to the Journal of Microbiology, Immunology and Infection guidelines 21

Guideline Summary for Management of Pan‑Drug‑Resistant Acinetobacter baumannii in Critically Ill Adults

Empirical Therapy Considerations

• Indications for empirical coverage of PDR A. baumannii – Initiate empirical therapy when a patient has a documented history of colonisation with carbapenem‑resistant A. baumannii (CRAB), is cared for in an intensive‑care unit where ≥ 25 % of isolates are CRAB, or presents with septic shock after recent healthcare exposure. 22
• Impact of prior colistin exposure – Previous treatment with colistin raises the risk of heteroresistance and subsequent therapeutic failure. 23

Definitive (Targeted) Therapy

• Verification of true pan‑resistance – Resistance to all carbapenems, polymyxins, sulbactam, tigecycline, aminoglycosides, and fluoroquinolones should be confirmed by broth micro‑dilution testing. 23
• Detection of heteroresistance – Heteroresistant subpopulations may appear as colonies within inhibition zones on susceptibility plates and should be sought when pan‑resistance is suspected. 23
• Recommended combination backbone for severe infections – When any component shows in‑vitro activity (e.g., sulbactam MIC ≤ 8 mg/L), a triple regimen is advised: high‑dose ampicillin‑sulbactam plus colistin plus a third agent (tigecycline, rifampicin, or fosfomycin). 23

Combinations to Avoid

• Colistin + rifampicin (two‑drug) regimen – This pairing lacks demonstrated clinical benefit and is associated with a higher risk of hepatotoxicity; it should not be used. 23
• Colistin + glycopeptides (e.g., vancomycin) – Combining colistin with vancomycin increases nephrotoxicity without providing additional antimicrobial effect; it should be avoided. 23

Monitoring Requirements

• Liver‑function monitoring with rifampicin – Weekly assessment of hepatic enzymes is recommended when rifampicin is part of the regimen because of a significant hepatotoxicity risk. 23